LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers

By LabMedica International staff writers
Posted on 21 Apr 2023
Image: A new test detects biological markers related to several types of cancer (Photo courtesy of Freepik)
Image: A new test detects biological markers related to several types of cancer (Photo courtesy of Freepik)

When assessing potential cancer cases, physicians rely on biomarker tests to aid in diagnosis. These tests, utilizing a testing system and patient samples, enable doctors to explore possible indicators and narrow down their search for the most accurate and effective treatment. Now, researchers have devised a novel test to identify biological markers associated with various cancer types.

A team of chemists at Florida State University (Tallahassee, FL, USA) has created a sensing platform made of a gold nanoparticle and dye-labeled peptide molecules. These components are linked by chemical bonds, with the gold nanoparticle preventing the dye from emitting light under UV exposure. When a patient sample containing the enzyme MMP-14 – a biomarker for multiple cancer types, most commonly breast cancer – is introduced, it breaks the peptide bonds, separating the dye-containing fragment from the gold. In the absence of gold to absorb the dye's energy, the sample starts to emit light. The intensity of this light emission depends on the enzyme concentration and interaction duration. By analyzing this light, researchers can determine the presence and levels of a cancer marker in the sample.

Although there are already numerous tests to identify cancer in patients, this research represents an initial step towards developing a method capable of detecting a broader range of cancers. The research team has tested their system with the MMP-14 enzyme but intends to expand their efforts by pairing more peptide chains with other enzyme cancer markers. This advancement could eventually enable scientists to use a single test to simultaneously screen for various cancers. In addition to its diagnostic applications, the study also provides further insights into enzyme interactions with peptide-bound nanoparticles and the impact of enzyme addition on the testing system.

“Better tools for detecting cancer mean more effective treatment for patients,” said study co-author Hedi Mattoussi, a professor in the FSU Department of Chemistry and Biochemistry. “Our goal in this research was to build a biosensor that would light up in the presence of cancer markers, offering another tool for the ongoing problem of detecting this disease.”

Related Links:
Florida State University 

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Sample Transportation System
Tempus1800 Necto

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more